Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Abbott's XIENCE V(R) Superior To TAXUS(R) In Key Safety And Efficacy Measures In SPIRIT IV Trial
- Pixantrone Phase 3 Data To Be Presented At The 2009 American Society Of Clinical Oncology (ASCO) Annual Meeting
- GSK's HPV Cervical Cancer Vaccine Shows Superior Immune Response To Competitor Vaccine In First Head-to-head Study
- Aging With GRACE: New Health Care Delivery Model Improves Outcomes, Saves Money
- Enrollment In Study On Resuscitation Methods For Cardiac Arrest Stopped By NHLBI
- IAVI Statement On Results Of Phase III ALVAC-AIDSVAX Trial In Thailand
- ChemoCentryx Initiates Phase 2 Clinical Trial Of CCX354 For The Treatment Of Rheumatoid Arthritis
- Breast Cancer Survival Improves Herceptin Used With Chemotherapy
- FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
- New Updates To AHA/ACC/SCAI Clinical Guidelines Recommend Treatment With Effient(R) For Patients With Acute Coronary Syndromes Managed With PCI
Medtronic Issues Pacemaker Recall
Posted by: admin in Pharmacy Drugs on October 08th, 2009
LITTLE FALLS, N.J., June 12 — Certain pacemakers manufactured by Medtronic have been withdrawn from the market because of wiring problems, the FDA announced.
Of the more than 1.7 million Kappa and Sigma pacemakers implanted worldwide, about 21,300 are included in the recall.
They include devices in the Kappa Series 600/700/900 and Sigma Series 100/200/300 manufactured primarily between November 2000 and November 2002.
Patients can enter the serial number of their device at this Web site to find out whether it is included in the recall.
The FDA explained that the “devices may fail due to a separation of wires that connect the electronic circuit to other pacemaker components, such as the battery.”
In its letter to physicians, Medtronic estimated the failure rates of Kappa and Sigma pacemakers to be 1.1% and 4.8%, respectively.
In rare cases, patients who are pacemaker-dependent may experience serious injury or death resulting from the defect, the FDA said.